Microsatellite instability (MSI) has been associated with favourable survival in early stage colorectal cancer (CRC) compared to microsatellite stable (MSS) CRC. The BRAF V600E mutation has been associated with worse survival in MSS CRC. This mutation occurs in 40% of MSI CRC and it is unclear whether it confers worse survival in this setting. The prognostic value of KRAS mutations in both MSS and MSI CRC remains unclear. We examined the effect of BRAF and KRAS mutations on survival in stage II and III MSI colon cancer patients. BRAF exon 15 and KRAS exon 2-3 mutation status was assessed in 143 stage II (n=85) and III (n=58) MSI colon cancers by high resolution melting analysis and sequencing. The relation between mutation status and cancer-specific (CSS) and overall survival (OS) was analysed using Kaplan-Meier and Cox regression analysis. BRAF V600E mutations were observed in 51% (n=73) and KRAS mutations in 16% of cases (n=23). Patients with double wild-type cancers (dWT; i.e. BRAF and KRAS wild-type) had a highly favourable survival with 5-year CSS of 93% (95% CI 84-100%), while patients with cancers harbouring mutations in either BRAF or KRAS, had 5-year CSS of 76% (95% CI 67-85%). In the subgroup of stage II patients with dWT cancers no cancer-specific deaths were observed. On multivariate analysis, mutation in either BRAF or KRAS vs. dWT remained significantly prognostic. Mutations in BRAF as well as KRAS should be analysed when considering these genes as prognostic markers in MSI colon cancers.
INTRODUCTION
Colorectal cancer (CRC) is both clinically and biologically a heterogeneous disease. Microsatellite instability (MSI) occurs in 15% of CRC and results from a genetic or epigenetic defect in DNA mismatch repair (MMR), occurring sporadically (12%) or due to Lynch syndrome (3%). These cancers are more frequently right sided and often show poor differentiation, increased mucin formation and lymphocytic infiltration. 1 The crucial RAS-RAF-MEK-ERK signal transduction pathway is affected in both MSS and MSI CRC, and can be constitutively activated by mutations in KRAS or BRAF. BRAF V600E mutations in exon 15 occur in about 7% of MSS CRC and in 40% within the MSI subgroup. In MSI CRC, BRAF mutations are closely linked to sporadic disease, and rarely occur (1.4%) in Lynch syndrome CRC.
2,3 KRAS exon 2 and 3 mutations are found in approximately 35% of MSS CRC and variably (6-30%) in MSI CRC, [4] [5] [6] with frequencies up to 40% in Lynch syndrome associated CRC. 7 Co-occurrence of BRAF and KRAS mutations in CRC is an extremely rare event. 8 MSI confers good survival in stage II CRC compared to MSS 9, 10 , while in stage III the risk differences are limited. [9] [10] [11] [12] In stage IV CRC, however, MSI paradoxically confers worse survival than MSS CRC. 13, 14 MSI is found in 15-20% of stage II cancers, 7-13% in stage III and 3-8% of stage IV cancers. 9, 14, 15 Based on the stepwise change in the frequency and prognostic impact of MSI cancers it can be hypothesized that a subset of poor survival MSI cancers exists that progress to higher stages, while the majority of MSI cancers show a low rate of progression.
BRAF mutation and inconsistently KRAS mutations have been associated with worse survival in stage II and III MSS CRC. 16, 17 The prognostic effect and clinical significance of both BRAF and KRAS mutations in stage II and III MSI CRC is currently unclear. 1, 16 BRAF mutation correlates strongly with older age 16 and previous studies have mostly analysed its prognostic effect in MSI cancers univariately using overall survival (Supplementary Information Table 1 ). Also, despite BRAF and KRAS mutations being mutually exclusive and having complementary roles in the RAS-RAF-MEK-ERK signal transduction pathway, the prognostic effect of these mutations compared to double wild-type cancers (dWT;
i.e. BRAF and KRAS wild-type) has rarely been studied in MSI cancers before. Therefore, in the present study, we set out to analyse the prognostic importance of BRAF and KRAS mutations in stage II and III MSI colon cancers. 
MATERIALS AND METHODS

RESULTS
The prevalence of BRAF and KRAS mutations are presented in Table 1 . BRAF and KRAS mutations were observed in 51% (n=73) and 16% (n=23) of cases, respectively, and were mutually exclusive. BRAF mutations all comprised V600E. KRAS mutations occurred mostly in exon 2 (total n=20; codon 12, n=13; codon 13, n=6; both codon 12 and 13, n=1) and only rarely in exon 3 (total n=3; codon 59, n=2; codon 61, n=1). KRAS mutation status could not be determined in 4% of cases (n=5), which were BRAF WT. In 29% of cases (n=42) both BRAF and KRAS were WT (dWT).
BRAF mutation status was associated with higher age (p<0.01 Figure 1a ; Table 2 ).
For KRAS this was not statistically significant, which may well be explained by the low frequency When using OS as an end-point, BRAF or KRAS mutation status did not predict outcome in any of the analyses (Figure 1b, 1d and 1f ) . Of all the variables only patient's age predicted overall survival with the oldest age group demonstrating shorter survival compared to the reference age category (p=0.01).
Multivariate analysis
On multivariate CSS analysis either BRAF or KRAS mutation vs. dWT (p=0.04), tumour stage (p=0.03) and mucinous phenotype (p=0.07) were maintained in the final model (Table 2) .
Using OS as an end-point, higher patients' age (p<0.01) and grade of differentiation (p=0.03) significantly conferred worse survival, overruling all other variables, including BRAF and KRAS mutation status. 
DISCUSSION
In the present study, with 143 stage II and III MSI colon cancer patients, BRAF and KRAS mutations were found in 51% and 16% of cases, respectively, which compares to previous reports. The concomitant evaluation of both BRAF and KRAS mutation in MSI colon cancer provides useful prognostic information beyond evaluation of either variable separately. Most notably, patients with dWT cancers had a highly favourable survival with 5-year CSS of 93% (95% CI 84-100%) compared to patients with either BRAF or KRAS mutated cancers (5-year CSS 76%, 95% CI 67-85%). In the subgroup of stage II patients with dWT cancers no cancer-specific deaths were observed. On multivariate analysis mutation in either BRAF or KRAS vs. dWT remained significantly prognostic ( Table 2 ). In contrast to CSS, BRAF or KRAS mutation status vs. dWT did not demonstrate significant prognostic value on OS, although a tendency toward worse survival was observed in case mutations in these genes were present. However, since BRAF mutations are associated with older age, OS may not be the optimal endpoint for addressing this question in early stage colon cancer. Therefore CSS was chosen as the main endpoint in this study.
Several studies have presented data on the prognostic impact of BRAF mutation status in stage II and/or III MSI CRC (Supplementary Information Table 1 ). 5, 6, 11, [22] [23] [24] [25] [26] Some of these studies demonstrated a tendency toward worse survival for patients with a BRAF mutation in MSI cancers, although only one of these studies found BRAF mutation status to be significantly prognostic. 22 Of the studies that included patients with stage I through IV MSI CRC (Supplementary Information Table 1) 2,27-33 only one reported BRAF to be significantly prognostic. 29 Studies specifically on metastatic CRC have related the presence of BRAF mutation with worse survival within the MSI subset of CRC. 13, 14, 34 Except for one study, 32 previous studies have not found KRAS mutation status to have prognostic impact in the MSI subset of CRC. 4, 6, 11, 24 Importantly however, none of these studies analyzed the prognostic impact of KRAS mutated cancers versus dWT cancers.
In comparison to previous studies, the current study's design has certain advantages. First, unlike many previous studies (see Supporting Information Table 1 ) we used CSS and corrected multivariately for confounders, most notably patients' age. This is crucial due to the strong correlation of BRAF mutation with age. In concordance with previous literature, mutation in either BRAF or KRAS vs. dWT lost its prognostic significance in the current study when overall survival was used as an end-point.
Second, we compared either BRAF or KRAS mutated cancers to dWT cancers in our survival analyses.
This approach has been used previously for colorectal cancers but has rarely been applied when analyzing MSI tumors separately. This approach is logical, from a biological standpoint, considering that these mutations are mutually exclusive and are active in the same oncogenic pathway. The present study showed that mucinous adenocarcinoma was borderline significantly associated with worse survival compared to conventional adenocarcinoma on multivariate analysis. As a novel observation, we found no difference in CSS between well/moderately and poorly differentiated MSI cancers. This is of interest because grade of differentiation has generally been associated with survival in CRC 35 , although in those studies MSI was not distinguished from MSS. We also found no difference of survival between right and left colon cancers, as reported recently. 12 The main limitation of the present study is potential bias inherent to its retrospective design.
For this reason the effect of adjuvant chemotherapy could not be assessed. Furthermore, since the patients were diagnosed in 1987 through 2008 the chemotherapeutic regimens are likely to have varied. These most likely included 5-FU monotherapy, which may have a negative impact on survival. In addition, the data on high-risk factors in stage II CRC were incomplete and thus not taken along in the analysis.
In conclusion, BRAF and KRAS mutations show together a high prevalence in stage II and III MSI colon cancer and, when combined, are associated with poor survival compared to dWT cancers, which status confers an excellent cancer-specific survival. The concomitant evaluation of both BRAF and KRAS mutation in MSI colon cancers therefore provides useful prognostic information beyond evaluation of either variable alone.
